Enterococci increase the morbidity and mortality associated with severe intra-abdominal infections in elderly patients hospitalized in the intensive care unit

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 10, 2011, Pages 2379-2385

  Dupont, Hervé ^a,b   Friggeri, Arnaud ^a,b   Touzeau, Jérémy ^a   Airapetian, Norair ^a   Tinturier, François ^a   Lobjoie, Eric ^a   Lorne, Emmanuel ^a,b   Hijazi, Moustafa ^a   Ŕgimbeau, Jean Marc ^a   Mahjoub, Yazine ^a,b  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

Co morbidities; Organ failure; Prognosis

Indexed keywords

AMIKACIN; AMOXICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; GENTAMICIN; HYPERTENSIVE AGENT; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ABDOMINAL INFECTION; AGED; ANTIBIOTIC THERAPY; APPENDIX; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BACTEROIDES FRAGILIS; CANDIDA ALBICANS; COLON; COMMUNICABLE DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; FEMALE; GALLBLADDER; GERIATRIC PATIENT; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; MESOCOLON; MORBIDITY; MORGANELLA; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PANCREAS; PERITONEAL FLUID; PERITONITIS; POSTOPERATIVE INFECTION; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SERRATIA; SMALL INTESTINE; STAPHYLOCOCCUS; STOMACH; STREPTOCOCCUS; TREATMENT DURATION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

AGED; AGED, 80 AND OVER; CRITICAL ILLNESS; ENTEROCOCCACEAE; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE; INTRAABDOMINAL INFECTIONS; MALE; MULTIPLE ORGAN FAILURE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80052870169     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr308     Document Type: Article

References (44)

1. Vincent JL, Rello J, Marshall J et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323-9.
2. de Rooij SE, Abu-Hanna A, Levi M et al. Factors that predict outcome of intensive care treatment in very elderly patients: a review. Crit Care 2005; 9: R307.
3. Inui T, Haridas M, Claridge JA et al. Mortality for intra-abdominal infection is associated with intrinsic risk factors rather than the source of infection. Surgery 2009; 146: 654-62.
4. Mulier S, Penninckx F, Verwaest C et al. Factors affecting mortality in generalized postoperative peritonitis: multivariate analysis in 96 patients. World J Surg 2003; 27: 379-84.
5. Edelsberg J, Berger A, Schell S et al. Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surg Infect 2008; 9: 335-47.
6. Onderdonk AB, Bartlett JG, Louie T et al. Microbial synergy in experimental intra-abdominal abscess. Infect Immun 1976; 13: 22-6.
7. Burnett RJ, Haverstock DC, Dellinger EP et al. Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Surgery 1995; 118: 716-21; discussion 721-713.
8. Cercenado E, Torroba L, Canton R et al. Multicenter study evaluating the role of enterococci in secondary bacterial peritonitis. J Clin Microbiol 2010; 48: 456-9.
9. Gauzit R, Péan Y, Barth X et al. Epidemiology, management, and prognosis of secondary non-postoperative peritonitis: a French prospective observational multicenter study. Surg Infect 2009; 10: 119-27.
10. Sitges-Serra A, Lopez MJ, Girvent M et al. Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg 2002; 89: 361-7.
11. Wacha H, Hau T, Dittmer R et al. Risk factors associated with intraabdominal infections: a prospective multicenter study. Peritonitis Study Group. Langenbecks Arch Surg 1999; 384: 24-32.
12. Montravers P, Lepape A, Dubreuil L et al. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother 2009; 63: 785-94.
13. Sotto A, Lefrant J, Fabbro-Peray P et al. Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis. J Antimicrob Chemother 2002; 50: 569-76.
14. Gregoratos G. Infective endocarditis in the elderly: diagnosis and management. Am J Geriatr Cardiol 2003; 12: 183-9.
15. Koeijers JJ, Verbon A, Kessels AG et al. Urinary tract infection in male general practice patients: uropathogens and antibiotic susceptibility. Urology 2010; 76: 336-40.
16. Weinberg JM, Scheinfeld NS. Cutaneous infections in the elderly: diagnosis and management. Dermatol Ther 2003; 16: 195-205.
17. Vincent J-L, Sakr Y, Sprung CL et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34: 344-53.
18. Bonnet R. Bêtalactamines et enté robactéries. In: Courvalin P, Leclercq R, Bingen E, eds. Antibiogramme. Paris: Eska, 2006; 141-62.
19. McCabe WR, Jackson GG. Gram negative bacteremia, etiology and ecology. Arch Intern Med 1962; 110: 845.
20. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
21. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45: 197-203.
22. Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European-North American multicenter study. JAMA 1993; 270: 29057-68.
23. Vincent JL, Moreno R, Takala J et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22: 707-10.
24. Peng C, Lee K, Ingersoll G. An introduction to logistic regression analysis and reporting. J Educ Res 2002; 96: 3-14.
25. Montravers P, Andremont A, Massias L et al. Investigation of the potential role of Enterococcus faecalis in the pathophysiology of experimental peritonitis. J Infect Dis 1994; 169: 821-30.
26. Dupont H, Montravers P, Mohler J et al. Disparate findings on the role of virulence factors of Enterococcus faecalis in mouse and rat models of peritonitis. Infect Immun 1998; 66: 2570-5.
27. Plantefeve G, Dupont H, Hubert V et al. Impact of elements containing glycopeptide resistance genes on expression of virulence in Enterococcus faecalis peritonitis: a pilot study with rats. Antimicrob Agents Chemother 2003; 47: 1560-4.
28. Dupont H, Vael C, Muller-Serieys C et al. Prospective evaluation of virulence factors of enterococci isolated from patients with peritonitis: impact on outcome. Diagn Microbiol Infect Dis 2008; 60: 247-53.
29. Cattan P, Yin D, Sarfati E et al. Cost of care for inpatients with community-acquired intra-abdominal infections. Eur J Clin Microbiol Infect Dis 2002; 21: 787-93.
30. de Ruiter J, Weel J, Manusama E et al. The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis. Infection 2009; 37: 522-7.
31. Lucasti C, Jasovich A, Umeh O et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008; 30: 868-83.
32. Malangoni MA, Song J, Herrington J et al. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006; 244: 204-11.
33. Montravers P, Chalfine A, Gauzit R et al. Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections. Ann Surg 2004; 239: 409-16.
34. Roehrborn A, Thomas L, Potreck O et al. The microbiology of postoperative peritonitis. Clin Infect Dis 2001; 33: 1513-9.
35. Solomkin JS, Wilson SE, Christou NV et al. Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections. Ann Surg 2001; 233: 79-87.
36. Solomkin JS, Yellin AE, Rotstein OD et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 2003; 237: 235-45.
37. Augustin P, Kermarrec N, Muller-Serieys C et al. Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. Crit Care 2010; 14: R20.
38. Dupont H, Carbon C, Carlet J. Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The Severe Generalized Peritonitis Study Group. Antimicrob Agents Chemother 2000; 44: 2028-33.
39. Riche FC, Dray X, Laisne MJ et al. Factors associated with septic shock and mortality in generalized peritonitis: comparison between community-acquired and postoperative peritonitis. Crit Care 2009; 13: R99.
40. Chromik AM, Meiser A, Hölling J et al. Identification of patients at risk for development of tertiary peritonitis on a surgical intensive care unit. J Gastrointest Surg 2009; 13: 1358-67.
41. Nathens AB, Rotstein OD, Marshall JC. Tertiary peritonitis: clinical features of a complex nosocomial infection. World J Surg 1998; 22: 158-63.
42. Mosdell DM, Morris DM, Voltura A et al. Antibiotic treatment for surgical peritonitis. Ann Surg 1991; 214: 543-9.
43. Teppler H, McCarroll K, Gesser RM et al. Surgical infections with enterococcus: outcome in patients treated with ertapenem versus piperacillin-tazobactam. Surg Infect (Larchmt) 2002; 3: 337-49.
44. Rohrborn A, Wacha H, Schoffel U et al. Coverage of enterococci in community acquired secondary peritonitis: results of a randomized trial. Surg Infect (Larchmt) 2000; 1: 95-107.